Human Papillomavirus (HPV) Vaccine Market Research, 2030
The global Human Papillomavirus (HPV) Vaccine Market was valued at $3.9 billion in 2021, and is projected to reach $10.8 billion by 2030, growing at a CAGR of 12.4% from 2022 to 2030. Human papillomavirus (HPV) is indeed a viral illness that aims to spread via complexion contact. There are over 100 types of HPV, and over 40 of which have been transmitted via sexual activity and can affect your genital area, mouth, or neck. HPV is the most common infection, according to the Center of Disease Control and Prevention (CDC), it's so prevalent that even if those who have few sexual partners, most sexual activity people will experience a few variations of it at some point. Some instances of genitourinary HPV infection may not consequence in any health complications. However, definite types of HPV can cause infections and even cancers of the uterus, anus, and neck.
Human papillomavirus vaccination is used to treat individuals who have a viral infection that was spread from one person to another via skin contact. Cervarix and Gardasil, two human papillomavirus vaccines, are mostly used in females aged 9 to 30. Human papillomavirus (HPV) is a sexually transmitted infection as well. The HPV virus is distinct from the HIV and HSV virus, often referred to as herpes. The HPV vaccine protects the body from infection with several forms of human papillomavirus.
The increased prevalence of HPV-related diseases is driving up demand for HPV vaccinations, which is expected to be the primary driving factor for the worldwide human papillomavirus vaccine market opportunity during the forecast period. There are just three kinds of vaccines in the market: bivalent, quadrivalent, and nonavalent. All three vaccines are highly successful at avoiding infection with virus types 16 and 18, which are responsible for 70% of cervical cancer cures.
The global human papillomavirus vaccine market trends is segmented on the basis of type, disease indication, industrial vertical, and region. Based on type, the market has been divided into tetravalent, nonavalent, and bivalent. Based on disease indication, the market has been divided into cervical cancer, anal cancer, vulvar & vaginal cancer, penile cancer, oropharyngeal cancer, and others. Based on industrial vertical, the market has been divided into public and private alliances, government entities, physicians, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in this report include GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Sanofi S.A., Novartis AG, Serum Institute of India Pvt. Ltd., Bharat Biotech, Inovio Pharmaceuticals, Inc and Xenetic Biosciences, Inc. among others.
The human papillomavirus vaccine market is segmented into By Type, By Disease Indication and By Industry Vertical.
By Type
Nonavalent is fastest growing segment
By type, the tetravalent type sub-segment is predicted to have the maximum market share in the forecast period. The tetravalent human papillomavirus vaccine protects against HPV types 6, 11, 16, and 18. These human papillomavirus is responsible for 80% of cervical malignancies and at least 90% of genital warts cases worldwide.
By Disease Indication
Oropharyngeal cancer is fastest growing segment
By disease indication, cervical cancer indication sub-segment is predicted to have highest market share in terms of revenue. Rise in the cases of cervical cancer among the population is predicted to drive the sub-segment market in the estimated period. Cervical cancer rates remain high in underdeveloped countries, where more than 80% of cases are diagnosed. According to the World Health Organization, cervical cancer is the most common malignancy in women and the second leading cause of cancer-related death globally, accounting for over 300,000 fatalities per year. These factors are anticipated to boost the global human papillomavirus vaccine market size during the forecast period.
By Industry Vertical
Public and Private Alliances is the most lucrative segment
By industrial vertical, public and private alliances sub-segment is predicted to hold the highest share in terms of revenue in the estimated period. In most of the countries, public as well as private organizations collaborate for treating infections of the human papillomavirus. More such initiatives are predicted to drive the sub-segment market in the estimated period.
By region, Asia-Pacific dominated the global human papillomavirus vaccine market in 2021 and is forecasted to remain the fastest growing region during the forecast period. Increasing cases of cervical cancer and an increase in sexually transmitted diseases among the population are expected to be the primary driving factors for the market during the forecast period. Furthermore, an increase in major companies' investments in setting up vaccine manufacturing units across the region is expected to create more investment opportunities for the regional market during the forecast period.
IMPACT OF COVID-19 ON THE GLOBAL HUMAN PAPILLOMAVIRUS (HPV) VACCINE MARKET
- The coronavirus pandemic has caused unimaginable devastation as it has spread around the world in recent months, with thousands of deaths and millions of confirmed cases of the disease. To avoid contracting or spreading the disease, people are isolating themselves and avoiding public places and events around the world.
- Furthermore, epidemic has benefited the global market for human papillomavirus vaccinations. Despite the lockdown and the government controls set in response to the coronavirus epidemic, most healthcare personnel are carrying out their tasks, and companies are spending heavily in vaccine development.
- The increased population demand for HPV vaccine is likely to boost the market during a pandemic. The human papillomavirus is a deadly infection. Vaccine producers and other scientists are continually working on the development of HPV vaccines as well as COVID viral symptoms, which is predicted to boost the market in the next years.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the human papillomavirus vaccine market share, segments, current trends, estimations, and dynamics along with human papillomavirus vaccine market analysis from 2021 to 2030 to identify the prevailing HPV vaccine market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis assists to determine the prevailing the human papillomavirus vaccine market growth and market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global HPV vaccine market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global human papillomavirus vaccine market trends, key players, market segments, application areas, and market growth strategies.
Human Papillomavirus Vaccine Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Disease Indication |
|
 By Industry Vertical |
|
 By Region |
|
 Key Market Players | Novartis AG, Bharat Biotech., AstraZeneca, Sanofi, GlaxoSmithKline plc., Johnson & Johnson, Serum Institute of India Pvt. Ltd, Xenetic Biosciences, Inc., Inovio Pharmaceuticals, Inc, Merck & Co., Inc |
Analyst Review
According to the CXOs of the leading companies, the global human papillomavirus vaccine market possesses a substantial scope for growth in the future. Several companies are heavily investing in the development of other types of HPV vaccines for people of all ages. Vaccine demand is increasing rapidly in areas where supply is limited. As a result, companies are investing in developing another vaccine against the human papillomavirus with government assistance, which is expected to expand the market for investment opportunities. For example, the US Food and Drug Administration approved a supplemental application for Gardasil 9 in October 2018 for the treatment of women and men aged 27 to 45 years, which is expected to be the primary driving factor for the worldwide human papillomavirus vaccine market during the forecast period. According to the CXOs, Asia-Pacific is projected to register faster growth as compared to North American and European markets.
Rapid expansion of HPV associated diseases is increasing the demand of HPV vaccines industry in the human papillomavirus vaccine sector, along with rising awareness about human papillomavirus vaccine among people across the world, are projected to accelerate the growth of the human papillomavirus vaccine market.
Globally, rising occurrences of human papillomavirus (HPV)-associated malignancies of the anus, vulva, vagina, penis, and oropharynx, as well as rising demand for prevention of these infections, are driving the HPV vaccine market, all such factors will ultimately accelerate the global human papillomavirus vaccine market growth in the next few years.
Asia-Pacific will provide more business opportunities for global human papillomavirus vaccine market in the future.
Agreement, business expansion, and product launch are the key growth strategies of global human papillomavirus vaccine market players.
GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Sanofi S.A., Novartis AG, Serum Institute of India Pvt. Ltd., Bharat Biotech, Inovio Pharmaceuticals, Inc and Xenetic Biosciences, Inc. among others among others. are the leading market players active in the human papillomavirus vaccine market.
Loading Table Of Content...
